Results 51 to 60 of about 75,353,973 (171)

Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration [PDF]

, 2020
Purpose:The aim of this study was to compare outcomes of 3 loading doses of ziv-aflibercept and aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD).Design:Retrospective, nonrandomized, comparative study.Methods:This was a ...
Subramanyam, Anand, Pandey, Priti, Chhablani, Jay Kumar, Abhishek Heranjal, Apoorva Ayachit, Tiwari, Sarvesh, Jay Chhablani, Heranjal, Abhishek, Sarvesh Tiwari, Salti, Haytham I.S., Priti Pandey, Ahmad Mansour, Ayachit, Apoorva G., Mansour, Ahmad Mohammed Farid Mahmoud, Chattannavar, Goura, Goura Chattannavar, Mohamad A Mansour, Sumit Randhir Singh, Anand Subramanyam, Haitham Salti, Singh, Sumit Randhir, Mansour, Mohamad A.   +21 more
core   +1 more source

Real-world six-month outcomes after switching from aflibercept 2 mg to aflibercept 8 mg for neovascular age-related macular degeneration

Japanese Journal of Ophthalmology
Abstract Purpose To investigate 6-month outcomes in eyes with neovascular age-related macular degeneration (nAMD) switched from intravitreal aflibercept 2 mg to intravitreal aflibercept 8 mg.
Hiroya, Kindo, Mio Morizane, Hosokawa, Chihiro, Ouchi, Ryo, Matoba, Tetsuro, Morita, Junko, Hayashi, Yuki, Morizane   +6 more
openaire   +4 more sources

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C. Wykoff, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski   +12 more
wiley   +1 more source

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema

Therapeutic Advances in Ophthalmology
Summary What is this summary about? This is a summary of a publication about the PHOTON study, which was published in The Lancet . Diabetic macular edema (DME) is a serious and common complication of diabetes, with an estimated global prevalence of 5.5 ...
David M. Brown, David S. Boyer, Diana V. Do, Charles C. Wykoff, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Alyson J. Berliner, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Yenchieh Cheng, Delia Voronca, Rafia Bhore, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Xin Zhang, Sobha Sivaprasad   +22 more
doaj   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

Viability of Primary Human Pigment Epithelium Cells and Muller-Glia Cells after Intravitreal Ziv-Aflibercept and Aflibercept [PDF]

, 2016
Purpose: The aim of this study was to access the safety profiles of 2 fusion proteins with anti-vascular endothelial growth factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium cells and Muller-Glia cells in culture by assessing ...
Haritoglou, Christos, Wolf, Armin, Eibl, Kirsten, Rodrigues, Eduardo Buchele, Farah, Michel Eid [UNIFESP], de Andrade, Gabriel Costa [UNIFESP], Costa de Andrade, G., Wertheimer, Christian, Eibl, Kirsten H., Haritoglou, Christos [UNIFESP], Farah, Michel Eid, Rodrigues, Eduardo Buchele [UNIFESP], Kampik, Anselm   +12 more
core   +1 more source

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema

Therapeutic Advances in Ophthalmology
Summary What is this summary about? This is a summary of a publication about the 2-year (96-week) results from the PHOTON study, which was published in Ophthalmology . Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes.
Diana V. Do, Charles C. Wykoff, Sobha Sivaprasad, David M. Brown, David S. Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Zhanying Bai, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Zoran Hasanbasic, Peter J. Morgan-Warren, Xin Zhang, Alyson J. Berliner   +23 more
doaj   +1 more source

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola, Pekko Hujanen, Hannu Uusitalo, Hannele Uusitalo‐Järvinen   +3 more
wiley   +1 more source

Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study

British Journal of Ophthalmology
Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with
Arianna Paris, Giulio Volpe, Kathrin Perruchoud-Ader, Alex Casanova, Moreno Menghini, Gabriela Grimaldi   +5 more
openaire   +2 more sources